893 karma · joined December 16, 2023
And that’s setting aside “sandboxes” that are just instruction-based restrictions on what executables may be called. Anything that isn’t a deterministic external filter _will_ be ignored at some point.
I’m on a tiny team building an application that’s unlikely to ever average more than a handful or two of concurrent active users.
We’re using DB replicas for redundancy and failover and may eventually use the read replica to remove load off the primary. We’re using caching (which comes almost “for free” with our framework) to save slow/resource-intensive expensive DB and third-party API queries for lookups against rarely changing data sets.
We run background jobs and need at-least-once processing, which means consumers must be idempotent; not to mention idempotent handling of webhooks from one of our vendors. In fact, I can’t think of a small company I’ve worked at beyond proof of concept stage that hasn’t needed idempotence and benefitted from caching some things.
My last small company dealt with high volume and needed rate limiting and outboxes. In other highish volume contexts I’ve pre-computed expensive data structures (idempotently) and cached them in a document database.
Next time you’re at a small company might be a time to look around and ask yourself if any of these patterns is needed or would improve your software’s reliability or performance.
This won’t work for all classes of bug, but helps a lot.
Also helpful: extensive logging, telemetry, and exception capture with not just stack but context; session recordings to video (the service we use for that blanks out user inputs for privacy purposes but lets you see where things went wrong).
And people drag luggage around on city streets all the time. Many tourist destinations are pedestrian cities even outside their most central downtown areas. And luggage also needs to be dragged around hotels — and in suburban areas their absurdly large parking lots.
The skate wheels are a plausible argument, though.
I’ve installed a utility on my laptop that supports “sub-zero” display dimming for nighttime use because monitors are now over-optimized for max brightness, with min brightness being retina-searing for eyes adjusted to a dim room.
For me, this one doesn’t seem to have enough accuracy to be worth the trouble.
But a few years of improvements and maybe a blood test like that is what you need to get insurance to cover a baseline neurological evaluation plus re-evaluation every few years to see whether it’s time to start aggressive treatment.
Maybe in another decade aggressive treatment will be available for disease at earlier stages and good enough to prevent progression at all and maintain nearly full quality of life.
This isn’t a game changer right now, but every time something like this makes it through trials it gives me a bit more hope that we will in fact beat this thing. Likely within my lifetime. Maybe even before I succumb to it.
With the original course of treatment complete we then transitioned to a maintenance regimen of … I can’t remember the name off the top of my head but it’s the other one that’s similar but a bit less aggressive — they had originally presented it as one of the possibilities when we were deciding to start treatment. They’re also adding on a neuroplastocity-enhancing drug as a complement, along with some occupational therapy.
Best of luck to you and your family!
The risk of dangerous side effects seems to be much higher for those with APOE4 — before approving the treatment they required among other things a genetic test ruling that out. (There are several other genetic variants that predispose to Alzheimer’s, fwiw.) We were lucky and saw none of the concerning side effects.
Are we “there” yet? Where’s there?
The prognosis after this treatment is a massive improvement over what it would have been at this stage of progression if it had been reached even 5 years ago.
If you can detect the disease even earlier and halt progress at a point where you retain more cognitive function, that’s a huge win — and gives you time to wait it out a bit longer in hope that we’re able to develop a treatment that doesn’t just pause but can reverse progression.
Yeah, I doubt we’re ready yet to administer these drugs to people who are asymptomatic (not to mention how pricey they currently are). But for someone who likely has the genes for it, just _knowing_ would in some ways be a relief.